Spruce Biosciences (SPRB) Debt to Equity (2022 - 2025)
Spruce Biosciences (SPRB) has disclosed Debt to Equity for 4 consecutive years, with $0.1 as the latest value for Q3 2025.
- On a quarterly basis, Debt to Equity rose 140.8% to $0.1 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.1, a 140.8% increase, with the full-year FY2024 number at $0.06, up 38.81% from a year prior.
- Debt to Equity was $0.1 for Q3 2025 at Spruce Biosciences, up from $0.07 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.1 in Q3 2025 to a low of $0.04 in Q3 2024.
- A 4-year average of $0.06 and a median of $0.05 in 2022 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: tumbled 39.19% in 2023, then surged 140.8% in 2025.
- Spruce Biosciences' Debt to Equity stood at $0.07 in 2022, then crashed by 39.19% to $0.04 in 2023, then soared by 38.81% to $0.06 in 2024, then surged by 65.19% to $0.1 in 2025.
- Per Business Quant, the three most recent readings for SPRB's Debt to Equity are $0.1 (Q3 2025), $0.07 (Q2 2025), and $0.09 (Q1 2025).